Breaking News

Almac Discovery Licenses Cancer Drug

April 29, 2013

Shin Poong to develop and market ALM201 in South Korea

Almac Discovery has licensed its novel anti-angiogenic peptide ALM201 to Shin Poong Pharmaceutical Co. Ltd. for clinical development and marketing in South Korea. Almac will receive an undisclosed upfront payment, milestones and royalties. Almac Discovery will pursue its own development program in Europe and is seeking partners for ALM201 in all other territories.
 
ALM201 is a highly potent anti-angiogenic peptide targeted to cells expressing CD44 and acts by inhibiting migration of vascular endothelial cells. The compound has completed preclinical development with a good toxicology profile and is entering Phase I/II trials in the UK.
 
Stephen Barr, president and managing director of Almac Discovery, said, “We are delighted to be partnering with Shin Poong. Their work on ALM201 in South Korea will complement our own program very well and will add significant scientific value.”
 
Mr. Won June Chang, chief executive officer of Shin Poong, said, "We are delighted to license the novel and innovative anti-cancer drug candidate from Almac Discovery and we look forward to supporting the development of this drug candidate in South Korea."

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems